Skip to main content
CDT
NASDAQ Life Sciences

Insider Andrew Regan Buys $190K in Open Market, Increases Stake to 5.4%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1.9
Mkt Cap
$10.3M
52W Low
$1.775
52W High
$1,229.7
52W Position info
7.0% above low
Off High info
100% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CDT is trading near its 52-week low of $1.775 (7.0% above the low).

Summary

Andrew Regan, CEO of Corvus Capital Ltd., made a $190,000 open market purchase of CDT Equity Inc. shares, increasing his beneficial ownership to 5.4%.


Key Events · Ownership and Investor Activity · CDT

  • Insider Open Market Purchase

    Corvus Capital Ltd., controlled by CEO Andrew Regan, purchased 100,000 shares in the open market for $190,000 on May 13, 2026.

  • Warrant Exercise

    Corvus Capital Ltd. received 147,401 shares on March 24, 2026, through a cashless exercise of pre-funded warrants, after the 1-for-25 reverse stock split.

  • Increased Beneficial Ownership

    Andrew Regan now beneficially owns 262,766 shares, representing 5.4% of the company's outstanding common stock.


Analysis · CDT · Life Sciences

This filing indicates a significant vote of confidence from Andrew Regan, CEO of Corvus Capital Ltd., who increased his beneficial ownership through a $190,000 open market purchase. This buying activity is particularly notable given the company's recent disclosures of a going concern warning and substantial share dilution events, suggesting strong conviction in the company's future despite financial challenges.

How filings like this one have moved

In the 30 days to Sep 10, 2026, 43.7% of the 583 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CDT was trading at $1.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.3M. The 52-week trading range was $1.78 to $1,229.70. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CDT - Latest Insights

CDT
Sep 08, 2026, 5:30 PM EDT
Filing Type: S-1
Importance Score:
9
Price at Filing: $0.6168
Real-time Price: $0.582 info
Change: -$0.0348 (-6%) info
Market Cap: $8.218M info
CDT
Sep 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.622
Real-time Price: $0.582 info
Change: -$0.040 (-6%) info
Market Cap: $8.218M info
CDT
Sep 02, 2026, 6:10 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.925
Real-time Price: $0.582 info
Change: -$0.343 (-37%) info
Market Cap: $8.218M info
CDT
Sep 01, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.48
Real-time Price: $0.582 info
Change: -$0.898 (-61%) info
Market Cap: $8.218M info
CDT
Sep 01, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.58
Real-time Price: $0.582 info
Change: -$0.998 (-63%) info
Market Cap: $8.218M info